Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylit
Ankylosing spondylitis (AS) is a chronic, inflammatory autoimmune disease characterized by axial bone inflammation. The main clinical manifestations include back pain and progressive spinal rigidity, as well as inflammation of the hips, shoulders, and peripheral joints. Also, extra-articular manifestations, such as pso
| Condition(s) | Ankylosing Spondylitis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Ankylosing spondylitis (AS) is a chronic, inflammatory autoimmune disease characterized by axial bone inflammation. The main clinical manifestations include back pain and progressive spinal rigidity, as well as inflammation of the hips, shoulders, and peripheral joints. Also, extra-articular manifestations, such as psoriasis, uveitis, and inflammatory bowel disease (IBD). Indicators of inflammation such as erythrocyte sedimentation rate (ESR) and Creactive protein (CRP), which are typically elevated in AS patients, particularly when peripheral joints are involved, these tests ultimately do not reflect the disease process and have limited sensitivity and specificity. Disease activity in AS has been measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), which includes o |
| Who can participate | Inclusion Criteria: * Patients fulfill the Assessment in Spondyloarthritis International Society (ASAS) classification criteria for Axial Spondyloarthritis. * Patients with disease duration more than 6 months. * Patients who failed conventional treatment and on bDMARDs (IL17 or Anti-TNF-α). * Age above 16 years old. * Patient cooperative and can answer questions. * Patients who are able and willing to give written informed consent. Exclusion Criteria: * Other rheumatologic or collagen diseases. * Age below 16 years and above 60 years. * Uncooperative patients. * Patient not able and willing to give written informed consent. * Patient with other causes of platelet dysfunction, count irregularity. |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Sohag University |
| Locations | Sohag, Egypt |
| Start date | 2024-10-01 |
| NCT ID | NCT06642207 |
| Official listing | https://clinicaltrials.gov/study/NCT06642207 |